Molecular Characterization of Multiple Myeloma Ethnic Disparity

多发性骨髓瘤种族差异的分子特征

• 批准号: 9137629
• 负责人: Carl Ola Landgren
• 金额: $ 10.6万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-10 至 2018-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9137629
• 关键词: Molecular; Characterization; Multiple; Myeloma; Ethnic

ABSTRACT Despite that multiple myeloma (MM) in Blacks clearly has a biologically different natural history, clinically, Blacks are assessed using the same genetic approaches as the whole population. The proposed project will afford us the opportunity to identify and characterize MM in the Black population with much higher genetic and molecular resolution. It will answer questions such as whether Blacks have, in general, better survival because of the presence of more low risk genetic aberrations and whether these changes alter the effect of treatment drug. Our conclusions may have immense regulatory impact. For example, certain MM therapies may be indicated sooner in the treatment course in Blacks. Alternatively, some therapies may be found to have minimal efficacy and indication in Blacks with certain molecular subtypes. This proposal will be the first study to characterize the molecular subtypes of MM in Blacks in a systematic fashion, investigate the effect of these on novel therapy outcomes, and potentially have major impact on regulatory approvals of future therapies. Therefore, it is imperative to focus on this under-represented population and at least begin to understand the differences in MM pathophysiology, which may ultimately lead to improved outcomes.

摘要